Author: Nichols Martin|| Date Published: July 31, 2020
Pharmaceutical company GlaxoSmithKline has been awarded a $342M contract by the U.S. Army to obtain COVID-19 vaccines in mass quantities from multiple vendors.
The service branch obligated the full contract amount at the time of award to support coronavirus response efforts at military sites within and outside the continental U.S., the Department of Defense said Thursday.
Army Contracting Command received one bid for the procurement.
Contract work will take place at Research Triangle Park in North Carolina through Feb. 28, 2021.
HawkEye 360, provider of space-based signals intelligence, has acquired Innovative Signal Analysis, a Dallas, Texas-based company manufacturing high-performance signal-processing technologies.…
The Defense Health Agency awarded a combined $8.07 billion in contracts to Humana Government Business, Evernorth Federal Services and Ipsos Public Affairs…
